Woodford Blog: Will Pfizer Make Another Bid for Astra?

Media speculation is already gathering pace on the subject of whether Pfizer will return with a renewed bid – affecting not just shareholders but potentially the wider UK economy

Woodford Funds 18 November, 2014 | 1:14PM
Facebook Twitter LinkedIn

Morningstar's "Perspectives" series features investment insights from third-party contributors. Here, in the latest blog from the Woodford Funds website, star UK equity income fund manager Neil Woodford discusses the prospects for the Pfizer deal with AstraZeneca. 

Following its aborted takeover advances earlier this year, Pfizer (PFE) can return to make a renewed bid for AstraZeneca (AZN) once the six month ‘lock-out’ expires on November 26. Media speculation is already gathering pace on the subject of ‘will they? / won’t they?’ return with a renewed bid – it would be a big deal, in more ways the one, affecting not just shareholders but potentially the wider UK economy and healthcare patients globally.

At this stage, I suspect there is a 50/50 likelihood that Pfizer will approach AstraZeneca again. Some things have changed to make a deal less likely. The increased political opposition to ‘tax inversion’ deals, for example, where US companies buy overseas companies as a way of reducing their domestic tax obligations. This has already scuppered Abbvie’s (ABBV) proposed acquisition of Shire and some commentators suggest Pfizer’s attraction towards AstraZeneca may have cooled somewhat for the same reason.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
AbbVie Inc108.40 USD-1.00Rating
AstraZeneca PLC8,994.00 GBX-0.10Rating
Pfizer Inc42.97 USD-1.35Rating

About Author

Woodford Funds  is an investment management company founded by UK equity income specialist Neil Woodford.